Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05978193 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma

Study acronym: SCR-ESCC-01
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 160 to 100v2 Show 5 more changesShow less
    • Primary completion date: Jan 1, 2026 to Jan 2027
    • Primary endpoints: 1 to 2
    • Study completion date: Jan 1, 2027 to Jan 1, 2028
    • Study description expanded, about 112 words
    • Study arms: 2 to 3
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
SCR-ESCC-01 is a multicenter, randomized, phase II study aiming to investigate the benefit of early involvement of low-dose radiotherapy(LDRT) and conventionally fractionated radiotherapy(CFRT) in the first-line anti-PD-1 based treatment of metastatic ESCC. It begins with a safety run-in phase, followed by a randomized controlled comparison against standard immunochemotherapy.
Trial Details
NCT Number NCT05978193
Lead Sponsor Shanghai Chest Hospital
Conditions
(from sponsor)		 Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Metastatic Esophageal Squamous Cell Carcinoma
Related terms Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov